Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice

Author： Gandhi Sanjay K.   Järbrink Krister   Fox Kathleen M.   Brandrup-Wognsen Gunnar  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.12, 2009-12, pp. : 2817-2828

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Abstract Objective:This article reviewed the collective evidence from routine clinical practice to summarize the existing literature on the effectiveness of rosuvastatin in treating hypercholesterolemia. Methods:A comprehensive Medline literature search identified all published articles, in all languages, from January 2003 through September 2008 on the use of rosuvastatin in the usual-care setting. The search identified 60 articles, and 16 articles were included in this review because they were observational and non-interventional and included sufficient data specific to rosuvastatin. Excluded articles were clinical trials, cost-effectiveness models, safety, reviews, pharmacokinetics, abstracts or editorials only, or all statins combined. Included rosuvastatin articles were categorized as (1) effectiveness in general population and (2) effectiveness in special populations (e.g., elderly, diabetes). Results:Seven studies consistently showed that diverse patients from different geographic regions who were newly initiated on rosuvastatin had significantly greater reduction in low-density lipoprotein cholesterol (LDL-C) (29–52%) compared with patients treated with other statins (16–43%). LDL-C goal attainment as recommended by National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III or European Society of Cardiology (ESC) guidelines was consistently and significantly higher among patients treated with rosuvastatin (64–81%) compared with patients treated with other statins (34–73%). Rosuvastatin-treated patients with diabetes or HIV or who were elderly had significantly greater LDL-C reduction and LDL-C goal attainment compared with patients treated with other statins. Limitations:Channeling bias or confounding by indication may have influenced the results of the real-world studies, if physicians reserve rosuvastatin for sicker or more difficult to treat patients. Conclusions:There is a strong and consistent body of evidence demonstrating the effectiveness of rosuvastatin in lowering LDL-C and LDL-C goal attainment in real life compared with other statins at commonly prescribed doses, which reflects the existing evidence from clinical trials.

Related content

LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results

By Heintjes Edith M.   Hirsch Mark W.   van der Linden Michiel W.   O'Donnell John C.   Stalenhoef Anton F.   Herings Ron M.C.  

Current Medical Research and Opinion, Vol. 24, Iss. 8, 2008-08 ,pp. : 2241-2250 (10)

Informa Healthcare

Access to resources Recommend Favorite

Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States

By Fox Kathleen M.   Gandhi Sanjay K.   Ohsfeldt Robert L.   Blasetto James W.   Bays Harold E.  

Current Medical Research and Opinion, Vol. 23, Iss. 9, 2007-09 ,pp. : 2125-2133 (9)

Informa Healthcare

Access to resources Recommend Favorite

The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin

By Fonseca Francisco A. H.   Ruiz Alvaro   Cardona-Muñoz Ernesto G.   Silva Jose M.   Fuenmayor Nery   Marotti Marcelo  

Current Medical Research and Opinion, Vol. 21, Iss. 8, 2005-08 ,pp. : 1307-1316 (10)

Informa Healthcare

Access to resources Recommend Favorite

Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

By Athyros Vasilios G.   Mikhailidis Dimitri P.   Papageorgiou Athanasios A.   Symeonidis Athanasios N.   Daskalopoulou Stella S.   Kakafika Anna I.   Pehlivanidis Anthimos N.   Bouloukos Vasilios I.   Langer Anatoly    

Current Medical Research and Opinion, Vol. 20, Iss. 9, 2004-09 ,pp. : 1385-1392 (8)

Informa Healthcare

Access to resources Recommend Favorite

The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients: the rosuvastatin monotherapy looks to be insufficient

By Mark Laszlo   Paragh György   Reiber Istvan  

Current Medical Research and Opinion, Vol. 27, Iss. 10, 2011-10 ,pp. : 1959-1960 (2)

Informa Healthcare

Access to resources Recommend Favorite